Learn More
BACKGROUND Palonosetron, a highly selective and potent 5-HT(3) receptor antagonist with a strong binding affinity and a long plasma elimination half-life (approximately 40 hours), has shown efficacy(More)
The objective of this multicenter, phase II, open-label study was to evaluate the safety and efficacy of the newest 5-hydroxytryptamine3 (5-HT3) receptor antagonist, palonosetron, plus dexamethasone(More)
8262 Background: PALO is the only 5-HT3 receptor antagonist (RA) approved by the FDA for prevention of acute & delayed CINV after moderately emetogenic CT. Aprepitant is a NK1 RA approved for(More)
680 Background: Clinical benefit from cytotoxic CT is observed largely in those patients with objective clinical response (OCR). This may not be the case, however, for targeted biologic agents with(More)
  • 1